Dunad Therapeutics Announces Appointment of Chief Business Officer
CAMBRIDGE, England--(BUSINESS WIRE)--Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insights from chemistry and protein degradation, today announced the hire of Ruben Tommasi, Ph. D., as Chief Research and Development Officer. In this role, Dr. Tommasi will lead global R&D strategy and be responsible for cultivating Dunad’s pipeline growth and lead programs.
CAMBRIDGE, England--(BUSINESS WIRE)--Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insights from chemistry and protein degradation, today announced it has appointed Pearl Huang, Ph.D., as Chief Executive Officer.
TORONTO, Nov. 4, 2021 /PRNewswire/ - Dalriada is pleased to congratulate Dunad Therapeutics on its strategic collaboration and license agreement with Novartis potentially worth $1.35 billion, to generate orally bioavailable covalent and protein degrading small molecule drugs. This leading-edge technology has the potential to deliver next-generation therapeutics with advantages over traditional drugs against a wide range of diseases by unlocking access to disease-causing and often undruggable targets.
Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally bioavailable covalent and protein degrading small molecule drugs.